Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
REGENXBIO Inc. is a biotechnology company focused on the development, commercialization, and licensing of gene therapy medicines. The company operates within the biotechnology and gene therapy industries, with a core emphasis on treatments for rare diseases, retinal disorders, and neurodegenerative conditions. Its business is centered on the discovery and application of adeno-associated virus (AAV) vectors to deliver therapeutic genes to target cells, enabling long-term protein expression after a single administration.
The company’s primary revenue drivers include product sales, licensing fees, and collaboration revenue derived from its proprietary AAV gene delivery platform. REGENXBIO is uniquely positioned due to its foundational intellectual property surrounding the NAV® AAV8, AAV9, and AAVrh10 vectors, which are among the most widely used AAV serotypes in clinical development. Founded in 2008, REGENXBIO emerged from research conducted at the University of Pennsylvania and has since evolved from a platform licensing company into an organization advancing wholly owned clinical-stage gene therapy products while maintaining a broad partner ecosystem.
Business Operations
REGENXBIO conducts its operations through a single integrated operating segment focused on gene therapy research, development, and commercialization. The company generates revenue from the sale of its approved product ZOLGENSMA® royalty interests, licensing its NAV® Technology Platform, and from collaboration and sublicense agreements with pharmaceutical and biotechnology partners. Its clinical pipeline includes both in-house development programs and partnered programs utilizing its vector technologies.
Operationally, REGENXBIO manages preclinical research, clinical trial execution, regulatory strategy, and manufacturing oversight, while leveraging third-party contract manufacturers for vector production. The company maintains strategic partnerships with multiple biopharmaceutical firms that have licensed its AAV technology for use in independently developed gene therapy candidates. These partnerships span therapeutic areas including ophthalmology, neurology, metabolic disorders, and oncology.
Strategic Position & Investments
REGENXBIO’s strategic direction emphasizes advancing a focused portfolio of late-stage gene therapy candidates while continuing to monetize its NAV® platform through selective licensing. Growth initiatives include progressing its internally developed programs for retinal diseases and rare genetic disorders, as well as optimizing manufacturing processes to support future commercial launches. The company has prioritized disciplined capital allocation and portfolio refinement to concentrate resources on programs with the highest probability of regulatory approval and commercial impact.
Notable investments include continued funding of clinical trials for its lead candidates and maintaining intellectual property protections around its AAV vectors. REGENXBIO does not operate as a diversified holding company but maintains economic interests in partnered programs through milestone payments and royalties. The company is actively involved in emerging applications of gene therapy, including next-generation vector design and improved delivery efficiency.
Geographic Footprint
REGENXBIO is headquartered in the United States, with its principal offices located in Maryland. The company’s primary research and corporate operations are U.S.-based, while its clinical development activities extend internationally through global clinical trial sites. These trials involve patients and investigators across North America, Europe, and select regions in Asia-Pacific, depending on the indication and study design.
Although REGENXBIO does not maintain extensive international manufacturing or commercial infrastructure, its global footprint is expanded through licensing partners that operate worldwide. As a result, the company’s NAV® technology has a broad international presence, with gene therapy products in development and on the market across multiple continents through third-party collaborators.
Leadership & Governance
REGENXBIO is led by an experienced executive team with backgrounds in biotechnology, pharmaceuticals, and gene therapy development. The leadership emphasizes scientific rigor, regulatory discipline, and long-term value creation through innovation in genetic medicine.
- Curran M. Simpson – President and Chief Executive Officer
- Christina Chan – Chief Financial Officer
- Steve Pakola – Chief Medical Officer
- Dan Baker – Chief Legal Officer and Corporate Secretary
- Nick Leschly – Founder and Board Member
The company’s governance framework is designed to support regulatory compliance, transparent reporting, and strategic oversight, with a board of directors that includes executives with experience in life sciences, capital markets, and corporate governance.